Tỷ lệ tiêu chảy và các yếu tố liên quan trong điều trị ung thư phổi không tế bào nhỏ có đột biến EGFR bằng thuốc ức chế Tyrosine Kynase tại Bệnh viện Ung bướu Nghệ An=Diarrhea rate and related factors in the treatment of EGFR mutant non- small cell lung cancer with Tyrosine Kinase inhibitors at Nghe An Oncology Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Hoàng Mai Đậu, Thị Yến Lê, Khánh Toàn Nguyễn, Thị Tú Uyên Nguyễn, Thị Hải Nụ Trần

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Y Dược Thái Bình (Đại học Y Dược Thái Bình), 2024

Mô tả vật lý: tr.4-9

Bộ sưu tập: Metadata

ID: 244350

Thêm vào giỏ

Chúng tôi tiến hành nghiên cứu này nhằm xác định tỉ lệ tiêu chảy và các yếu tố liên quan sau sử dụng EGFR TKIs trong điều trị ung thư phổi không tế bào nhỏ giai đoạn IV tại Bệnh Viện Ung Bướu Nghệ An.Phương pháp: Nghiên cứu mô tả hồi cứu trên 105 bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IV được điều trị bằng thuốc EGFR TKIs tại Bệnh Viện Ung Bướu Nghệ An từ tháng 2/2021 đến tháng 2/2023. Kết quả: Tuổi trung bình là 65,3
phần lớn là nhóm tuổi ≥ 60 (chiếm 71,4%), nữ giới chiếm tỷ lệ 54,3%, không hút thuốc lá 56,2%, mô bệnh học chủ yếu là Carcinoma tuyến (86,7%). Tỷ lệ tiêu chảy chung khi dùng EGFR TKIs là 26,7%, trong đó chủ yếu là tiêu chảy độ 1 và độ 2 chiếm 14,3 % và 10,5%, có 2 trường hợp tiêu chảy độ 3 chiếm 1,9%. Tiêu chảy gặp tỷ lệ cao nhất ở nhóm sử dụng Afatinib (56,3%) và thấp nhất ở nhóm sử dụng Gefitinib (6,7%)Kết luận: Tiêu chảy là tác dụng phụ thường gặp trên bệnh nhân sử dụng thuốc EGFR TKIs. Afatinib là thuốc gây tiêu chảy tỷ lệ cao nhất so với các thuốc EGFR TKI khác.We conducted this study to determine the rate of diarrhea and related factors after using EGFR TKIs in the treatment of stage IV non-small cell lung cancer at Nghe An Oncology Hospital. Method: A retrospective descriptive study on 105 stages IV non-small cell lung cancer patients treated with EGFR TKIs at Nghe An Oncology Hospital from February 2021 to February 2023. Results: The mean age is 65.3
most of them are ≥ 60 years old (accounting for 71.4%), females accounted for 54.3%, non-smokers 56.2%, histopathology is mainly adenocarcinoma (86.7%). The overall rate of diarrhea when using EGFR TKIs was 26.7%, of which mainly grade 1 and grade 2 diarrhea accounted for 14.3% and 10.5%, and 2 cases of grade 3 diarrhea accounted for 1.9%. Diarrhea was highest in the Afatinib group (56.3%) and lowest in the Gefinib group (6.7%). Conclusion: Diarrhea is a common side effect in patients using EGFR TKIs. Afatinib is the drug that causes the highest rate of diarrhea compared to other EGFR TKI drugs.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR